Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.74 |
| ▸ | MMP8 | P22894 | 4/20 | 0.74 |
| ▸ | MMP13 | P45452 | 2/20 | 0.74 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.74 |
| ▸ | MMP2 | P08253 | 13/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MMP12 | P39900 | 3/20 | 0.55 |
| ▸ | MMP14 | P50281 | 3/20 | 0.55 |
| ▸ | MMP3 | P08254 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5182861 | 1.00 | MMP9 (0.74) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL255603 | 1.00 | MMP9 (0.74) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| Water SCHEMBL30893957 | 0.99 | MMP9 (0.72) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL28937664 | 0.99 | MMP9 (0.72) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL29186820 | 0.99 | MMP9 (0.72) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| Toluene SCHEMBL7906483 | 0.96 | MMP9 (0.78) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL8448575 | 0.92 | MMP2 (0.67) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL3458998 | 0.89 | MMP9 (0.76) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL21538609 | 0.89 | MMP9 (0.76) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| Potassium Ion SCHEMBL30893958 | 0.89 | MMP9 (0.59) | MMP9MMP8MMP13ADAMTS4MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800881-A | Recovery method of levamisole hydrochloride resolving agent N-p-toluenesulfonyl-L- (+) -glutamic acid | 常州齐晖药业有限公司 | 2024-04-02 | — | — | CN | claimed |
| US-20190002394-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | CODY LABORATORIES, INC. | 2019-01-03 | — | — | US | claimed |
| US-20170057909-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | ALTER DOMUS (US) LLC | 2017-03-02 | — | — | US | claimed |
| CN-100341850-C | Salts of demethyl phencynonate isomer and N-para-methyl-phenyl-sulfuryl glutamic acid optical isomer and their preparing method and use | INST OF POISONOUS MEDICINE ACA (CN) | 2007-10-10 | — | — | CN | claimed |
| CN-1781904-A | Salts of demethyl phencynonate isomer and N-para-methyl-phenyl-sulfuryl glutamic acid optical isomer and their preparing method and use | INST OF POISONOUS MEDICINE ACA (CN) | 2006-06-07 | — | — | CN | claimed |
| CN-117800881-A | Recovery method of levamisole hydrochloride resolving agent N-p-toluenesulfonyl-L- (+) -glutamic acid | 常州齐晖药业有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117800881-A | Recovery method of levamisole hydrochloride resolving agent N-p-toluenesulfonyl-L- (+) -glutamic acid | 常州齐晖药业有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117800881-A | Recovery method of levamisole hydrochloride resolving agent N-p-toluenesulfonyl-L- (+) -glutamic acid | 常州齐晖药业有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2019208721-A1 | HAIR MOISTURIZER, WHITENING AGENT, AND WHITENING COSMETIC | 株式会社成和化成 (JP) | 2019-10-31 | — | — | WO | disclosed |
| US-20190002394-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | CODY LABORATORIES, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20170349534-A1 | A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE | HARMAN FINOCHEM LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-20170349534-A1 | A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE | HARMAN FINOCHEM LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| EP-0573473-B1 | 4-[(2-benzothiazolyl)methylamino]-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol | JANSSEN PHARMACEUTICA NV (BE) | 1995-12-13 | — | — | EP | disclosed |
| US-5434168-A | ANTISTROKE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-07-18 | — | — | US | disclosed |
| EP-0573473-A1 | 4- (2-BENZOTHIAZOLYL)METHYLAMINO]--g(a)- (3,4-DIFLUOROPHENOXY)METHYL]-1-PIPERIDINEETHANOL. | JANSSEN PHARMACEUTICA NV (BE) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992014731-A1 | 4-[(2-BENZOTHIAZOLYL)METHYLAMINO]-α-[(3,4-DIFLUOROPHENOXY)METHYL]-1-PIPERIDINEETHANOL | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-03 | — | — | WO | disclosed |
| EP-0501552-A1 | 4-[(2-Benzothiazolyl)methylamino]-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-02 | — | — | EP | disclosed |
| US-4906622-A | Optically active 2-chloro-12-(3-dimethylamino-2-methyl-propyl)-12H-dibenzo[d.g] [1,3,6] dioxazocines and a process for the preparation thereof | EGIS GYOGYSZERGYAR (HU) | 1990-03-06 | — | — | US | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349534-A1 | A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE | OPRK1, OPRM1, CYP2D6 | MMP9 3437/4885MMP8 4544/4885MMP13 2599/4885 |
| US-20170057909-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | CYP2D6, COMT, AADAT | MMP9 4493/4885MMP8 3083/4885MMP13 3702/4885 |
| US-20190002394-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | CYP2D6, COMT, AADAT | MMP9 4493/4885MMP8 3083/4885MMP13 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.